Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Metabolic Disorders

US probes Novo Nordisk's marketing of diabetes medicines

This article was originally published in Scrip

Executive Summary

Novo Nordisk has received a subpoena from the US Attorney for the District of Massachusetts, which has called for the production of documents regarding "potential criminal offences" relating to the company’s marketing and promotion of several diabetes medications, including NovoLog (insulin aspart), Levemir (insulin detemir) and Victoza (liraglutide), according to a statement from the firm.

Table

View full table

Topics

Tags:
Metabolic Disorders
Latest Headlines

Cash-Rich SynOx Well Placed To Compete In Hot TGCT Field

Quick Listen: Scrip's Five Must-Know Things

Avistone Wins China Approval For First C-Met Inhibitor In Glioblastoma

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

See All
UsernamePublicRestriction

Register

SC011915

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By